Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 9/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427791 | 0.88 | PARP1 (0.39) | TLR7TLR8TLR9PARP1KIT | |
| SCHEMBL3427546 | 0.85 | TLR8 (0.40) | TLR7TLR8TLR9PARP1KIT | |
| SCHEMBL3421275 | 0.80 | CHEK1 (0.43) | PARP1 | |
| SCHEMBL3428325 | 0.78 | CHEK1 (0.42) | PARP1 | |
| SCHEMBL3427361 | 0.76 | GSK3B (0.49) | TLR7TLR8TLR9PARP1FGFR1 | |
| SCHEMBL3426316 | 0.74 | GSK3B (0.47) | TLR7TLR8TLR9PARP1FGFR1 | |
| SCHEMBL3421444 | 0.73 | GSK3B (0.47) | PARP1KITFGFR1KDRFLT1 | |
| SCHEMBL3428892 | 0.72 | CHEK1 (0.44) | — | |
| SCHEMBL3425881 | 0.70 | GSK3B (0.49) | TLR7TLR8TLR9PARP1KIT | |
| SCHEMBL3427264 | 0.68 | GSK3B (0.48) | PARP1FGFR1KDRFLT1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | GSK3B, GSK3A, PDXK | TLR7 4348/4885TLR8 4807/4885TLR9 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.